jnj-73763989
Nucleic acidexperimental
Clinical trial activity
15 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2019 (NCT04002752)
Timeline
Indications
Mechanism of action
- Hepatitis B virusANTISENSE INHIBITOR
Hepatitis B virus antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095455 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06537414 | Phase 2 | Nov 25, 2024 | GlaxoSmithKline |
| NCT05275023 | Phase 2 | Jun 30, 2022 | — |
| NCT05123599 | Phase 1 | Nov 26, 2021 | Janssen Pharmaceutica NV |
| NCT05005507 | Phase 2 | Nov 3, 2021 | Janssen Pharmaceutica NV |
| NCT04963738 | Phase 1 | Sep 22, 2021 | Janssen Pharmaceutica NV |
| NCT04667104 | Phase 2 | Feb 1, 2021 | Janssen Pharmaceutica NV |
| NCT04585789 | Phase 2 | Jan 15, 2021 | Janssen Pharmaceutica NV |
| NCT04586439 | Phase 1 | Nov 24, 2020 | Janssen Pharmaceutica NV |
| NCT04535544 | Phase 2 | Sep 17, 2020 | Janssen Pharmaceutica NV |
| NCT04439539 | Phase 2 | Sep 14, 2020 | Janssen Pharmaceutica NV |
| NCT04208386 | Phase 1 | Jan 7, 2020 | Janssen Pharmaceutica NV |
| NCT04288310 | Phase 2 | Nov 6, 2019 | Janssen Pharmaceutica NV |
| NCT04129554 | Phase 2 | Nov 4, 2019 | Janssen Pharmaceutica NV |
| NCT03982186 | Phase 2 | Jul 17, 2019 | Janssen Pharmaceutica NV |
| NCT04002752 | Phase 1 | Jul 1, 2019 | Janssen Pharmaceutica NV |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 13 | 13 | 2 | 2019 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1